We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > vamorolone

News List

Positive results in Duchenne muscular dystrophy (DMD) trial europeanpharmaceuticalreview
October 09, 2020
Interim trial results suggest vamorolone may offer a superior alternative to long-term treatment with high-dose glucocorticoids in young Duchenne muscular dystrophy (DMD) patients.
Santhera to Obtain Worldwide Rights to Vamorolone americanpharmaceuticalreview
September 07, 2020
Santhera Pharmaceuticals has signed agreements with Idorsia and ReveraGen BioPharma, making Santhera a direct license holder of vamorolone.
Santhera obtains exclusive licence to DMD drug vamorolone pharmaceutical-technology
September 04, 2020
Santhera Pharmaceuticals has entered agreements with Idorsia and ReveraGen BioPharma to gain exclusive global rights to Duchenne muscular dystrophy (DMD) drug, called vamorolone.